The Global Health Body Sounds Concern Over Critical Lack of Obesity Jabs
Fewer than a tenth of people eligible to benefit from weight-loss injections such as Wegovy can access them, warns the WHO as it publishes its first advice on the drugs.
Given in excess of 1,000,000,000 people worldwide currently obese, it is calling for broader and more equitable access to this class of drugs.
Per forecasts, more than two billion will be living with obesity by 2030 unless action is taken.
"The latest guidance recognises that obesity is a long-term condition that can be treated with thorough and ongoing treatment," stated the agency's head Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and logistical bottlenecks are key obstacles to universal availability to the injections that can aid individuals in losing substantial body mass, explains the agency.
Weight-Loss Drug Supply Crisis
Despite the present most favorable case, the production of these medications might only reach approximately 100 million people – under 10% of eligible patients, per the WHO.
The recommendation encourages governments and firms to increase availability, through measures including licensing agreements.
Exclusive production rights on the active ingredient – the primary ingredient of Novo Nordisk's Wegovy – is due to expire in multiple nations in 2026.
How Weight-Loss Injections Function
The injections imitate a natural hormone to slow digestion, reduce hunger and boost satiety so people eat less.
Individuals usually begin shedding pounds within a few weeks of beginning the regular doses.
Studies indicates people may regain a significant portion within a year of discontinuing the drug, because their usual food cravings return.
To be above a healthy weight raises your chance for developing health problems, like type 2 diabetes, heart disease, brain attack, and certain malignancies.
Obesity concerns individuals in countries worldwide and was responsible for 3.7 million fatalities worldwide in 2024, per the health agency.
